2020
The Company’s share capital has, in connection with the registration of the directed share issue, increased to DKK 945,526.80...
28 February, 2020
Year-End Report 2019
Morten Albrechtsen, CEO of FluoGuide, comments: “I would like to thank all shareholders – new and from the IPO for the...
17 February, 2020
Communiqué from extraordinary general meeting in FluoGuide A/S
Item 1: Authorisation to the board of directors to increase the share capital at market price or at a rate discounted to the market...
31 January, 2020
Extraordinary General Meeting
The board of directors hereby convenes an extraordinary general meeting of FluoGuide A/S, CVR no. 39 29 64 38, (the ”Company”)...
29 January, 2020
FluoGuide proposes directed share issue to strengthen its ownership and shorten the time to market for FG001
FluoGuide provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide’s first product, FG001...
15 January, 2020
Excellent result of FluoGuide’s FG001 guiding surgical removal of cancer is published
The study aimed at investigating the resection of the human pancreatic cancer using an orthotopic xenograft pancreatic cancer model...
9 January, 2020
Safety study initiated with FG001
FluoGuide’s FG001 is designed to be well tolerated and its two main components have both demonstrated excellent tolerability...
FluoGuide’s first product FG001 lights up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to...
2019
29 November, 2019
Interim Report Third Quarter 2019
Morten Albrechtsen, CEO of FluoGuide, comments: “We are very pleased that the supply chain for FG001 has been established to...